Page 104 - 2020年19期

dation of a health policy model of type 2 diabetes in Chi- US setting[J]. J Med Econ，2018，21（5）：497-509.
nese setting[J]. J Comp Eff Res，2018，7（8）：749-763. [21] 王芳旭，陶立波.德谷胰岛素对比甘精胰岛素在基础胰岛
[12] POLLOCK RF，VALENTINE WJ，MARSO SP，et al. 素联合餐时胰岛素疗法中治疗中国 2 型糖尿病的成本-
Long-term cost-effectiveness of insulin degludec versus 效用分析[J].中国药物经济学，2019（7）：9-13、35.
insulin glargine U100 in the UK：evidence from the basal- [22] EDDY DM，HOLLINGWORTH W，CARO JJ，et al. Mo-
bolus subgroup of the DEVOTE trial（DEVOTE 16）[J]. del transparency and validation：a report of the ISPOR-
Appl Health Econ Health Policy，2019，17（5）：615-627. SMDM modeling good research practices task force-7[J].
[13] VIRIATO D，CALADO F，GRUENBERGER JB，et al. Value in Health，2012，15（6）：843-850.
Cost-effectiveness of metformin plus vildagliptin com- [23] PALMER AJ，Mount Hood 5 Modeling Group，CLAKE P，
pared with metformin plus sulphonylurea for the treat- et al. Computer modeling of diabetes and its complica-
ment of patients with type 2 diabetes mellitus：a Portu- tions：a report on the fifth mount hood challenge meet-
guese healthcare system perspective[J]. J Med Econ， ing[J]. Value in Health，2013，16（4）：670-685.
2014，17（7）：499-507. [24] GERSTEIN HC，MILLER ME，BYINGTON RP，et al. Ef-
[14] CHIN KL，OFORI-ASENSO R，Si S，et al. Cost-effective- fects of intensive glucose lowering in type 2 diabetes[J]. N
ness of first-line versus delayed use of combination dapa- Engl J Med，2008，358（24）：2545-2559.
gliflozin and metformin in patients with type 2 diabe- [25] ASCHE CV，HIPPLER SE，EURICH DT. Review of mo-
tes[J]. Sci Rep，2019. DOI：10.1038/s41598-019-40191-8. dels used in economic analyses of new oral treatments for
[15] GOURZOULIDIS G，TZANETAKOS C，IOANNIDIS I， type 2 diabetes mellitus[J]. Pharmacoeconomics，2014，32
et al. Cost-effectiveness of empagliflozin for the treatment （1）：15-27.
of patients with type 2 diabetes mellitus at increased car- [26] GU S，WANG X，QIAO Q，GAO W，WANG J，DONG H.
diovascular risk in Greece[J]. Clin Drug Investig，2018，38 Cost-effectiveness of exenatide twice daily vs insulin
（5）：417-426. glargine as add-on therapy to oral antidiabetic agents in
[16] NGUYEN E，COLEMAN C I，NAIR S，et al. Cost-utility patients with type 2 diabetes in China[J]. Diabet Obes
of empagliflozin in patients with type 2 diabetes at high Metab，2017，19（12）：1688-1697.
cardiovascular risk[J]. J Diabet Complications，2018，32 [27] CHAROKOPOU M，MCEWAN P，LISTER S，et al. The
（2）：210-215. cost-effectiveness of dapagliflozin versus sulfonylurea as
[17] POLLOCK RF，VALENTINE WJ，MARSO SP，et al.DE- an add-on to metformin in the treatment of type 2 diabetes
VOTE 5：evaluating the short-term cost-utility of insulin mellitus[J]. Diabet Med，2015，32（7）：890-898.
degludec versus insulin glargine U100 in basal- bolus regi- [28] CHAROKOPOU M，SABATER FJ，TOWNSEND R，et al.
mens for type 2 diabetes in the UK[J]. Diabet Ther，2018， Methods applied in cost-effectiveness models for treat-
9（3）：1217-1232. ment strategies in type 2 diabetes mellitus and their use in
[18] EVANS M，CHUBB B，GUNDGAARD J. Cost-effective- Health Technology Assessments：a systematic review of
ness of insulin degludec versus insulin glargine in adults the literature from 2008 to 2013[J]. Curr Med Res Opin，
with type 1 and type 2 diabetes mellitus[J]. Diabet Ther， 2015，32（2）：207-218.
2017，8（2）：275-291. [29] American Diabeteds Association Consensuspanel. Gui-
[19] EVANS M，GUNDGAARD J，HANSEN BB. Cost-effec- delines for computer modeling of diabetes and its compli-
tiveness of insulin degludec/insulin aspart versus biphasic cations[J]. Diabet Care，2004，27（9）：2262-2265.
insulin aspart in patients with type 2 diabetes from a Da- [30] CARO JJ，BRIGGS AH，SIEBERTU，et al. Modeling
nish health-care perspective[J]. Diabetes Ther，2016，7 good research practices-overview：a report of the ISPOR-
（4）：809-823. SMDM modeling good research practices task force-1[J].
[20] CHAKRAVARTY A，RASTOGI M，DHANKHAR P， Value in Health，2012，15（6）：796-803.
et al. Comparison of costs and outcomes of dapagliflozin （收稿日期：2020-03-24 修回日期：2020-08-17）
with other glucose-lowering therapy classes added to met- （编辑：刘明伟）
formin using a short-term cost-effectiveness model in the

·2398 · China Pharmacy 2020 Vol. 31 No. 19 中国药房 2020年第31卷第19期